Molecular imaging of tumor-infiltrating macrophages in a preclinical mouse model of breast cancer

Theranostics

Volumn 5, Issue 6, 2015, Pages 597-608

  Sun, Xianlei ^a   Gao, Duo ^a   Gao, Liquan ^a   Zhang, Chenran ^a   Yu, Xinhe ^a   Jia, Bing ^a   Wang, Fan ^a,b   Liu, Zhaofei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b INSTITUTE OF BIOPHYSICS   (China)

Author keywords

CD206; Image guided therapy; Macrophage depletion; Optical imaging; Tumor associated macrophage

Indexed keywords

ANTIBODY; CD206 ANTIBODY; DOCETAXEL; DYE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CELL SURFACE RECEPTOR; IMIDAZOLE DERIVATIVE; LECTIN; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; TAXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG UPTAKE; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOFLUORESCENCE; LUNG METASTASIS; MOLECULAR IMAGING; MOUSE; NEAR INFRARED IMAGING SYSTEM; NONHUMAN; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; FEMALE; LUNG TUMOR; MACROPHAGE; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; NEAR INFRARED SPECTROSCOPY; PATHOLOGY; PROCEDURES; SECONDARY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; DIPHOSPHONATES; FEMALE; IMIDAZOLES; LECTINS, C-TYPE; LUNG NEOPLASMS; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MANNOSE-BINDING LECTINS; MICE; MICE, INBRED BALB C; RECEPTORS, CELL SURFACE; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY, NEAR-INFRARED; TAXOIDS;

EID: 84934874184     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11546     Document Type: Article

References (37)

1. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5: 591-602.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-49.
3. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-92.
4. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41: 49-61.
5. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4: 71-8.
6. Pollard JW. Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol. 2008; 84: 623-30.
7. Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006; 116: 2132-41.
8. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124: 263-6.
9. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013; 332: 3-10.
10. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization:tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23: 549-55.
11. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012; 33: 119-26.
12. Ezekowitz RA, Gordon S. Alterations of surface properties by macrophage activation: expression of receptors for Fc and mannose-terminal glycoproteins and differentiation antigens. Contemp Top Immunobiol. 1984; 13: 33-56.
13. Choi KM, Kashyap PC, Dutta N, et al. CD206-positive M2 macrophages that express heme oxygenase-1 protect against diabetic gastroparesis in mice. Gastroenterology. 2010; 138: 2399-409, 409e1.
14. Movahedi K, Schoonooghe S, Laoui D, et al. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012; 72: 4165-77.
15. Put S, Schoonooghe S, Devoogdt N, et al. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med. 2013; 54: 807-14.
16. Green JR. Antitumor effects of bisphosphonates. Cancer. 2003; 97: 840-7.
17. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000; 289: 1504-8.
18. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001; 91: 1191-200.
19. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000; 88: 2961-78.
20. Liu Z, Sun X, Liu H, et al. Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models. J Nucl Med. 2014; 55: 818-23.
21. Sun X, Ma T, Liu H, et al. Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin alphavbeta3 and vascular endothelial growth factor. Eur J Nucl Med Mol Imaging. 2014; 41: 1428-39.
22. Liang C, Diao S, Wang C, et al. Tumor metastasis inhibition by imaging-guided photothermal therapy with single-walled carbon nanotubes. Adv Mater. 2014; 26: 5646-52.
23. Sun X, Yan Y, Liu S, et al. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med. 2011; 52: 140-6.
24. Zhang F, Zhu L, Liu G, et al. Multimodality imaging of tumor response to doxil. Theranostics. 2011; 1: 302-9.
25. Yoneda T, Michigami T, Yi B, et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000; 88: 2979-88.
26. Samoszuk M, Corwin MA. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer. 2003; 107: 159-63.
27. Locke LW, Mayo MW, Yoo AD, et al. PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes. Biomaterials. 2012; 33: 7785-93.
28. Niu M, Naguib YW, Aldayel AM, et al. Biodistribution and in vivo activities of tumor-associated macrophage-targeting nanoparticles incorporated with doxorubicin. Mol Pharm. 2014; 11: 4425-36.
29. Barrett T, Koyama Y, Hama Y, et al. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies. Clin Cancer Res. 2007; 13: 6639-48.
30. Yang L, Sajja HK, Cao Z, et al. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics. 2013; 4: 106-18.
31. Ma T, Sun X, Cui L, et al. Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med. 2014; 55: 1002-7.
32. Kobayashi H, Ogawa M, Alford R, et al. New strategies for fluorescent probe design in medical diagnostic imaging. Chem Rev. 2010; 110: 2620-40.
33. Zheng F, Devoogdt N, Sparkes A, et al. Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm. Immunobiology. 2015; 220: 200-9.
34. Melani C, Sangaletti S, Barazzetta FM, et al. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 2007; 67: 11438-46.
35. Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010; 16: 3420-30.
36. Coscia M, Quaglino E, Iezzi M, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010; 14: 2803-15.
37. Veltman JD, Lambers ME, van Nimwegen M, et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer. 2010; 103: 629-41.